• Info
  • Significant Ownership

Significant Ownership of TCG Crossover GP II, LLC

Signature - Title
/s/ Craig Skaling - Craig Skaling, Authorized Signatory
Location
Palo Alto, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by TCG Crossover GP II, LLC.

Notify me when TCG Crossover GP II, LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of TCG Crossover GP II, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RAPT RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share 10% $11,478,006 13,193,110 TCG Crossover GP II, LLC 27 Dec 2024
IPSC Century Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $15,978,987 17,754,430 Chen Yu 09 Jan 2026
ALEC Alector, Inc. Common Stock, par value $0.0001 per share 9.2% $29,600,000 10,000,000 Chen Yu 22 Oct 2025
ADVM Adverum Biotechnologies, Inc. Common Stock, par value $0.0001 per share 8.9% 1,871,482 TCG Crossover GP II, LLC 31 Mar 2025
LB Pharmaceuticals Inc. Common Stock, par value $0.0001 per share 7.8% 1,745,015 TCG Crossover GP II, LLC 12 Sep 2025
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.2% $32,812,836 4,427,705 Chen Yu 10 Oct 2025
TNGX Tango Therapeutics, Inc. Common Stock, par value $0.001 per share 6.3% $71,704,046 8,536,196 TCG Crossover GP II, LLC 30 Sep 2025
DNTH Dianthus Therapeutics, Inc. Common Stock, par value $0.001 per share 4.7% $32,660,322 1,501,624 TCG Crossover GP II, LLC 31 Mar 2025
CDTX Cidara Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 0 TCG Crossover GP II, LLC 30 Sep 2025
NKTR Nektar Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 -$110,015,928 0 -100% TCG Crossover GP II, LLC 30 Sep 2025

Schedules 13D/G Reported by TCG Crossover GP II, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.